



## AROA BIOSURGERY HALF YEARLY RESULTS WEBINAR

---

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on **Tuesday 26 November 2024, at 9 AM AEDT**, to discuss the Company's half year results.

Following discussion of half year results, leading US Surgeon Dr Anthony LaLama will deliver a presentation discussing the clinical challenges of lower extremity reconstruction, and the efficacy of AROA ECM™ products in achieving tissue coverage and closure for these patients.

Investors and interested parties can register to attend the webinar via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_XLsyCxWfSJcFRuflpN6Phg](https://us02web.zoom.us/webinar/register/WN_XLsyCxWfSJcFRuflpN6Phg)

Questions can be submitted before the webinar to [investor@aroa.com](mailto:investor@aroa.com) or during the webinar using the Q&A function on Zoom.

---

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

### **About Aroa Biosurgery:**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach.

AROA's products have been used in more than six million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). [www.aroabio.com](http://www.aroabio.com)

### **Contact**

[investor@aroabio.com](mailto:investor@aroabio.com)